^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    HLA-A*02

    i
    Other names: HLA-A, Major Histocompatibility Complex, Class I, A, HLA Class I Histocompatibility Antigen, A Alpha Chain, HLAA, HLA Class I Histocompatibility Antigen, A-1 Alpha Chain, MHC Class I Antigen HLA-A Heavy Chain, Leukocyte Antigen Class I-A, Human Leukocyte Antigen A
    Entrez ID:
    3105
    Related biomarkers:
    Expression
    Mutation
    Others
    1year
    🧐Is tebentafusp superior to combined ICI & other systemic treatments in metastatic uveal melanoma? A comparative efficacy analysis @OncologyAdvance https://t.co/5SWvBsPEsx 🔎44 trials 2682 pts 👉longest OS with tebentafusp in HLA-A*02:01+ pts (50% of pts) @myESMO @OncoAlert (@ArndtVogel)
    Clinical • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Kimmtrak (tebentafusp-tebn)
    1year
    SPOTLIGHT: @DavidHongMD @MDAndersonNews reported the safety and efficacy of Afamitresgene autoleucel (afami-cel), a MAGE-A4-targeting engineered TCR T cell therapy, in HLA-A*02+ patients with MAGE-A4-expressing solid tumors 👉 https://t.co/3JpeDSFvbM (@ACIR_org)
    Clinical
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02 • MAGEA4 expression
    |
    afamitresgene autoleucel (ADP-A2M4)
    over1year
    Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial | Nature Medicine https://t.co/QPFNVuRD3t (@Satyayadav__)
    Clinical
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    over1year
    ✨ High response rates (44%) of autologous T cell therapy for MAGE-A4-pos synovial sarcomas in HLA-A*02-restricted patients. Further confirmation trials and widening screening are warranted but it is encouraging for this rare tumor! @NatureMedicine @Sarcoma_papers @VivekSubbiah (@FlorentPeyraud)
    Clinical
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    over1year
    T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial https://t.co/sS5vamlinS (@VivekSubbiah)
    Clinical
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    over1year
    ⭐️Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A*02+ patients: a phase 1 trial @NatureMedicine ✅ORR = 24% (9/38) ✅7/16 (44%) for Synovial Sarcoma ✅2/22 (9%) for all other cancers. 👉Afamitresgene autoleucel 👉 Synovial sarcoma #Rarecancer has a new therapy ! (@VivekSubbiah)
    Clinical • P1 data
    |
    HLA-A (Major Histocompatibility Complex, Class I, A) • MAGEA4 (Melanoma antigen family A, 4)
    |
    HLA-A*02
    |
    afamitresgene autoleucel (ADP-A2M4)
    over1year
    When the FDA approved tebentafusp for the treatment of patients with HLA-A*02:01–positive unresectable or metastatic uveal melanoma in January 2022, it underscored 2 things about the treatment space in the disease. @Rdcarval @ColumbiaMed #melsm #oncology https://t.co/e2QVlJdExU (@OncLive)
    Clinical • FDA event • Metastases
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Kimmtrak (tebentafusp-tebn)
    over1year
    An orphan disease until recently. Every patient with uveal melanoma should be tested for HLA-A:02*01. Hopefully, more systemic therapies will come in the future. (@MunizThiago)
    Clinical
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    2years
    One question asked by many patients yesterday in clinic - what is their #TCR therapeutic option if they do not express HLA-A*02:01? My answer: #clinical #trials That is how we continue to make improvements in #uveal #melanoma (3/4) (@DrSapnaPatel)
    Clinical
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    2years
    ✅FDA approves tebentafusp-tebn for uveal melanoma 💡New class of drugs/mechanism of action within #immunotherapy. ➡️bispecific gp100 peptide-HLA-directed CD3 T cell engager for HLA-A*02:01➕adult pts ē #uvealmelanoma @oncoalert @asco ⁦@sitcancer⁩ https://t.co/jonVpGtmgF (@pashtoonkasi)
    Clinical • FDA event
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02
    |
    Kimmtrak (tebentafusp-tebn)
    2years
    The FDA approved the first T-cell receptor therapy tebentafusp-tebn for the treatment of adults with HLA-A*02:01-positive unresectable or metastatic uveal melanoma (@albanymd)
    FDA event
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02:01 • HLA-A*02
    |
    Kimmtrak (tebentafusp-tebn)
    2years
    💥FDA approves tebentafusp-tebn for uveal a bispecific gp100 peptide-HLA-directed CD3 T cell engager. ✅ HLA-A*02:01-positive patients with unresectable or metastatic uveal melanoma @OncoAlert https://t.co/11D5gaGwlS (@VivekSubbiah)
    Clinical • FDA event
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02:01 • HLA-A*02
    |
    Kimmtrak (tebentafusp-tebn)
    2years
    FDA Approves Tebentafusp-tebn in Adult HLA-A*02:01-Positive Unresectable/Metastatic Uveal Melanoma https://t.co/1jfoqIzqA1 via @targetedonc (@DrBonillaOnc)
    FDA event
    |
    HLA-A (Major Histocompatibility Complex, Class I, A)
    |
    HLA-A*02:01 • HLA-A*02
    |
    Kimmtrak (tebentafusp-tebn)